

2/a  
JE  
6/11/98

Express Mail Certif. no. EG646009268US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Docket No.: 2804-H

Serial No.: -- not yet assigned --

for prior application:

Filed: May 14, 1998

Examiner: Spector

Group Art Unit: 1812

For: CD30 LIGAND (as amended)

**PRELIMINARY AMENDMENT**

Box Patent Application  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Please amend the above-identified application as follows, prior to examination:

In the Specification:

Page 1, line 7, delete the current title and replace with -- CD30 LIGAND --.

Page 1, line 10, after "This application is" insert -- a divisional of U.S. application  
Serial No. 08/580,014, filed December 20, 1995, <sup>issued as US Pat No. 5,753,203</sup> ~~currently allowed~~, which is a divisional of  
U.S. application Serial No. 08/225,989, filed April 12, 1994, now U.S. Patent 5,480,981,  
which is --.

Page 1, line 11, delete "currently pending" and replace with -- now abandoned --.

In the Claims:

Cancel claims 1-26. Amend claims 27, 28, and 31 as follows:

27. (amended) A method of delivering a diagnostic or therapeutic agent to CD30<sup>+</sup> cells, comprising contacting said cells with a conjugate [according to claim 25] comprising a diagnostic or therapeutic agent attached to a CD30 ligand (CD30-L) polypeptide.

28. (amended) A method of delivering a diagnostic or therapeutic agent to CD30<sup>+</sup> cells, comprising contacting said cells with a conjugate [according to claim 26] comprising a diagnostic or therapeutic agent attached to a CD30-L polypeptide.

73